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Johne’s disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP)
is a major threat to the dairy industry and possibly some cases of Crohn’s disease in
humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding
would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy
of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control
vaccine using the protocol proposed by the Johne’s Disease Integrated Program (JDIP)
Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne’s
disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and
10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with
Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged
orally with a total of approximately 1.44 × 109 CFU divided in two consecutive daily doses
using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months
post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient
and valid model for JD challenge studies. None of the experimental or control vaccines
evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine
lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion
scores, but less than the control vaccine. Based on our results the relative performance
ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the
best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally
the 319 vaccine was the worst performer. The subcutaneously injected control vaccine
outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318)
do reduce presence of JD gross and microscopic lesions, slow progression of disease,
and one vaccine (329) reduced fecal shedding and tissue colonization.
Keywords: Mycobacterium avium subsp paratuberculosis, vaccine efficacy, mutant vaccines, diagnostic tests,
goats

INTRODUCTION
There are conflicting data on the ability of current vaccines for
Johne’s disease (JD) to reduce shedding of Mycobacterium avium
subspecies paratuberculosis (MAP), and killed “whole cell” MAP
vaccines often generate serious local tissue reaction and crossreactions to intradermal tests for M. bovis. This limits their
usefulness for control programs (Rideout et al., 2003). To date,
no vaccine has been developed that elicits an immune response
that completely eliminates viable MAP from the host (sterile
immunity). This is in part attributable to a lack of knowledge
of the factors that regulate the immune response to MAP or to
pathogenic mycobacteria in general (Flynn and Chan, 2001). Not
all animals exposed to MAP progress to clinical disease, but it is
unclear whether infection is never established in some animals
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or whether they develop an immune response that controls or
eliminates the pathogen (Rideout et al., 2003). Experimental trials with vaccinated animals challenged with virulent MAP or by
natural exposure have shown the beneficial effects of immunization (Saxegaard and Fodstad, 1985; Fridriksdottir et al., 2000;
Reddacliff et al., 2006; Stringer et al., 2013). Vaccination has
reduced the severity of lesions, reduced the frequency of clinical signs and delayed onset of disease (Harris and Barletta,
2001; Stringer et al., 2013). A vaccine that reduced the rate or
eliminated infection and reduced or eliminated fecal shedding
of the organism would be of tremendous value in JD control
programs if it could reduce disease prevalence (Rideout et al.,
2003). In addition to its use in a control program, an efficacious vaccine could significantly reduce production losses and
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premature culling or death losses that are associated with JD in
dairy cattle (Benedictus et al., 1987; NAHMS, 1997; Lombard
et al., 2005). Similar studies of losses associated with Johne’s
disease in beef, sheep and goat herds have not been reported,
but losses in these production systems are also likely to be
substantial.
Virtually all researchers using a JD challenge model have
been using different species of animals, challenge parameters,
doses of MAP, dosage intervals and strains of MAP. This dramatically increases the number of variables between studies and
makes direct comparison of challenge and vaccine efficacy trials very difficult and often impossible. A standardized challenge
model for use in vaccine efficacy trials is absolutely essential
to be able to directly compare the efficacy of various vaccine
formulations. A similar conclusion of the necessity of a standardized challenge model for vaccine efficacy studies was made in
August 2005 at the International Colloquium for Paratuberculosis
held in Copenhagen during the “Role of Vaccination” workshop session. The Johne’s Disease Integrated Program (JDIP)
Animal Model Standardization committee (AMSC) was created to address this issue and has published suggested international guidelines for JD challenge studies in multiple species
including cattle, sheep, goats, deer and mice (Hines et al.,
2007b).
Recent longitudinal JD studies presented at the 2010 JDIP
annual meeting in Denver, CO have suggested that JD management and environmental control practices have reduced the
incidence of JD, but are not likely to be successful in eradicating JD or reducing the incidence of JD to acceptable levels
within dairy herds. Subsequently, most JD researchers are of the
opinion that an effective vaccine which eliminates fecal shedding and prevents clinical disease is the best option for long
term control of JD. This led to the development of the JDIP
and USDA APHIS/NIFA sponsored JD vaccine project which
consisted of three blinded phases. Phase I consisted of evaluating vaccine candidates within in vitro macrophage studies
at two independent laboratories. Twenty-two JD vaccine candidates were submitted by JD researchers worldwide for enrollment in the Phase I project. Phase II consisted of evaluating
the best JD vaccine candidates as determined from the Phase
I project (8 vaccine candidates) within an in vivo mouse challenge model performed at two different laboratories. Phase III
consisted of evaluating the best five performing JD experimental
vaccines as determined by the results of Phase I and II within an
in vivo goat MAP challenge model using the AMSC recommended
parameters.
The objectives of the Phase III goat vaccine trial were
first to evaluate the efficacy of five MAP attenuated vaccine
strains against a commercially available MAP vaccine (Silirum®,
Pfizer) using the protocols and endpoints proposed by the
AMSC, and second to validate the AMSC Johne’s disease
goat challenge model (see Hines et al., 2007b). The design
of this study allows for a direct “head to head” comparison of the efficacy of the new experimental vaccines included
within the study to identify vaccine candidates for further
development.
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MATERIALS AND METHODS
EXPERIMENTAL DESIGN

Eighty goat kids were vaccinated orally twice at 8 and 10 weeks
of age with one of the attenuated vaccine strains or once subcutaneously at 8 weeks with Silirum®, or an oral sham control
vaccine consisting of pasteurized goat milk. Kids were challenged
orally with a total of 200 mg pelleted wet weight MAP (approximately 2.0 × 109 CFU) divided in 2 consecutive daily 100 mg
doses (approximately 1.0 × 109 CFU each) using bovine MAP
isolate ATCC-700535 (K10-like MAP strain). All experimental
and control groups had 10 kids/group. Table 1 lists the eight
experimental and control groups with treatments. Blood and fecal
samples were collected prior to vaccination (baseline samples)
and similar samples were collected monthly throughout the study.
Immunological tests evaluated include humoral response evaluation by AGID, ELISA, and cell mediated response by comparative
purified protein derivative (PPD) skin testing (M. avium, Johnin,
and M. bovis PPD’s). Kids within each group were euthanized and
necropsied at 13 months post-challenge. Gross and microscopic
lesions and relative number of acid-fast bacilli were evaluated
and scored at necropsy. Monthly fecal cultures and culture of
selected necropsy tissues (tonsil, submandibular lymph nodes,
liver, spleen, mesenteric lymph nodes, ileocecal lymph nodes,
duodenum, jejunum, ileum, and spiral colon) were performed
on Herrold’s egg yolk medium (HEYM) and CFU/g determined
for each specimen. Additional immunologic and diagnostic tests
including AGID, ELISA, intradermal skin testing, fecal PCR
and tissue PCR were performed throughout this study. Overall

Table 1 | Summary of experimental design and vaccines.
Experimental group

Vaccine
(description/mutant
insertion site)

Treatment

Group 1 (10 kids)

Negative control
(Sham vaccine)

Sham-vaccinated,
unchallenged

Group 2 (10 kids)

Control vaccine
(Silirum0® vaccine)

Vaccinated, challenged

Group 3 (10 kids)

316 vaccine
(between MAP3695
and FadE5)*

Vaccinated, challenged

Group 4 (10 kids)

315 vaccine
(MAP1566)*

Vaccinated, challenged

Group 5 (10 kids)

319 vaccine
(MAP1566)*

Vaccinated, challenged

Group 6 (10 kids)

318 vaccine
(between MAP0282c
and MAP0283c)*

Vaccinated, challenged

Group 7 (10 kids)

329 vaccine
(fabG2_2)**

Vaccinated, challenged

Group 8 (10 kids)

Positive control
(Sham vaccine)

Sham-vaccinated,
challenged

*Raúl G. Barletta mutant vaccine strains derived from K-10 by mutagenesis with

IS1096 derived transposons.
**Adel M. Talaat mutant vaccine strain (Shin et al., 2006).

www.frontiersin.org

March 2014 | Volume 4 | Article 26 | 2

Hines et al.

Experimental vaccines in Johne’s disease

necropsy lesion score for each animal was calculated by adding the
individual gross, microscopic and acid-fast stain scores as defined
in Table 2.
ANIMALS

The University of Georgia and Tifton Veterinary Diagnostic and
Investigational Laboratory have AALAC accredited animal facilities. Animal care was performed in accordance with the procedures of the University of Georgia Institutional Animal Care
and Use committee (UGA Animal Welfare Assurance # A343701). Two-month old kids were purchased from a farm with no
previous history of Johne’s disease where all the adult goats
were test negative by MAP serum ELISA (Parachek®, Biocor
Animal Health, Omaha, NE), AGID (New York State Animal
Health Diagnostic Laboratory method—personal communication, Susan Stehman, Cornell University, NY) and fecal cultures
were negative for MAP (this farm supplied the kids for the previous vaccine study—Hines et al., 2007a). The kids were moved
to the animal facilities at the Tifton Veterinary Diagnostic and
Investigational Lab, acclimated for 1 week and then randomly
assigned to one of 8 groups of 10 kids. The “pen effect” was
reduced by equalizing the distribution of kid sex and size between
pens. Baseline fecal and blood specimens were collected and
the initial PPD skin testing performed. The kids were vaccinated orally with the blinded attenuated JD vaccines from the
Kapur6 laboratory using two doses 2 weeks apart as per instructions provided. Each provided vaccine stock solution was blended
using a 1:4 ratio with pasteurized goat milk and each individual dose was drawn into a 5 ml syringe. Kids were allowed to
nurse the contents from the syringe or the contents were gently
expressed on the back of the tongue during administration. All
kids were housed in a restricted biosafety animal facility (BSL2). Kids within challenged groups were housed separately from
non-challenged groups in similar BSL-2 treatment rooms and
managed identically. No contact was allowed between challenged
and non-challenged groups at any time during the study. Free
choice coastal Bermuda hay was available to the kids throughout
the study. All kids were supplemented daily with a 10% protein
commercial goat ration with no added antibiotics at a mean rate
of 450 gm/kid/day. Goats were dewormed at monthly intervals

Table 2 | Scores for necropsy grading system categorized by lesion
severity and presence of acid-fast bacilli (AFB).
Severity

Gross

Microscopic

No. AFB

None

0

0

0.00

Mild

4

1

0.25

Moderate

8

2

0.50

Severe

12

3

0.75

Individual severity scores for each of the three categories were summed to
achieve the final lesion score for each kid at necropsy. Lowest and highest possible scores using this system are 0.0 and 15.75, respectively. The relative number
of AFB is given the least weight in this system since both paucibacillary and
pleuribacillary forms of JD are recognized in some affected animals without an
apparent major difference in disease severity.
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using a combination of Moxidectin (Fort Dodge Laboratories,
Fort Dodge, IA, USA) and Albendazole (Valbasen, Pfizer Animal
Health, New York, NY, USA) given orally. All kids were vaccinated
upon receipt (2 months old) with commercially-available tetanus
toxoid (Professional Biological Company, Denver, CO, USA) and
multivalent clostridial vaccine (Ultrabac 7, Pfizer Animal Health,
New York, NY, USA). Male kids were castrated prior to start of
the study (2 months old). Monthly blood and fecal samples were
collected from each kid as described in the protocol for each test
performed. All kids were necropsied at approximately 13 months
post-challenge.
ORGANISM

The MAP strain used in this study was a bovine isolate of
MAP ATCC—700535 (K10-like MAP strain) recovered from
experimentally infected calves at University of Pennsylvania (Ray
Sweeney) to help insure that virulent organisms are used for
challenge.
VACCINE PREPARATION AND ADMINISTRATION

The Silirum® vaccine was obtained directly from Pfizer Animal
Health and administered as a single dose according to manufacturer’s recommendations by subcutaneous injection. The five
experimental vaccines were cultured to equivalent optical densities (0.50 OD) and blinded (Table 1) off-site at Penn State
University before being shipped to UGA. After the goats in the
project had acclimated for 5 days, the experimental vaccines were
administered orally in two 5 ml doses 2 weeks apart in commercially pasteurized goat milk at approximately 1.0 × 108 organisms
per dose. The orally administered sham vaccines for the positive and negative control groups consisted of two 5 ml doses of
commercially pasteurized goat milk.
CHALLENGE PROTOCOL

The challenge inoculum was grown in Middlebrook 7H9 liquid media containing OADC, supplemented with mycobactin J
(Allied Monitor, Fayette, MO, USA) and 1% glycerol. All bacteria were freshly cultivated for approximately 12 weeks, and never
refrigerated or frozen prior to use. Organisms were pelleted by
centrifugation at 3000 × g for 10 min at RT in a pre-weighed
large cone-bottomed centrifuge tube and the supernatant discarded. After draining the excess fluid, an accurate wet weight
of the bacterial pellet was determined and the volume calculated to result in a final concentration of 20 mg organisms per
ml (Hines et al., 2007a,b). The inoculum was vortexed at maximum output for 2–3 min with three glass beads to break up
clumped bacilli. Whole commercially pasteurized goat’s milk was
added to 80% of final volume needed to make the inoculum
palatable and mixed by inversion thoroughly immediately prior
to use. All kids in all challenge groups were challenged at the
same time period 3 weeks after the last dose of vaccine given.
Each kid was allowed to nurse 5 ml of the inoculum (100 mg pelleted wet weight, approximately 1.0 × 109 CFU) from a syringe
or the inoculum was gently expressed on the back of the tongue.
Similar doses of inoculum were prepared and given on the next
day for a total of 2 doses (total of approximately 2.0 × 109 CFU).
The actual CFU of the inoculum was determined by dilution and
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plating on Middlebrook 7H10 agar plus OADC and mycobactin
J, and the total of both doses was found to be 1.44 × 109 CFU per
challenged animal.
GROSS AND MICROSCOPIC LESIONS

Technologies/Albion, Grand Island, NY) with an ABI 7900 RealTime Thermocycler in duplicate according to manufacturer’s
recommendations. Both cycle threshold (CT) values and positive/negative results were obtained on monthly fecal specimens
and tissues collected at necropsy. CT values ≤37 were considered
a positive result and inconclusive samples were repeated.

A complete detailed necropsy was performed on each animal by board-certified veterinary pathologists. Tissue specimens
obtained at necropsy were fixed in 10% buffered neutral formalin
overnight, processed routinely and embedded in paraffin blocks.
Serial sections were cut 4–6 μm thick and stained with H&E or
Kinouyan’s acid-fast stains. All specimens were described microscopically (blinded) by the same pathologist noting the presence,
location and number of granulomatous lesions and presence
and number of acid-fast bacilli. The combined gross and histologic descriptions for each animal were randomly scrambled,
then blindly rated and given a lesion score by another veterinary
pathologist unfamiliar with animal’s group and the vaccines used
within the study, but with extensive experience in the diagnosis of
JD. The lesion rating system (Table 2; Hines et al., 2007a,b) was
applied to the gross and histologic descriptions for each animal.
Individual lesion severity scores for gross and microscopic lesions,
and relative number of acid-fast bacilli, were summed to achieve
the final lesion score for each kid at necropsy.

To determine the persistence of the vaccine strains, primers
were designed to amplify target regions specific to the knockout mutant yet able to distinguish vaccine from challenge strains
based on product size. Colonies obtained from fecal culture slants
of HEYM were picked and placed in 30 ul of distilled water and
boiled for 5 min. The lysate was briefly centrifuged (13,000 × g,
1 min) and 5 ul was removed and used as template for amplification. Forward and reverse primers (Table 3) were added at
25 pmol each along with EconoTaq PLUS GREEN 2X master mix
(Lucigen Corp). IS900 amplification was used as a positive control
for all templates. The amplification conditions varied depending
on the vaccine strain tested and were 94◦ C for 1 min followed
by 25 cycles at 94◦ C for 30 s, 62◦ C for 30 s and 72◦ C for 2 min
followed by a hold at 72◦ C for 5 min.

FECAL AND TISSUE CULTURE

SEROLOGIC TESTS FOR MAP

Monthly fecal specimens were cultured using the sedimentation method currently recommended by National Veterinary
Services Laboratory (Whitlock et al., 2000) using Herrold’s egg
yolk medium (HEYM with ANV, BBL; Becton Dickinson and
Co, Sparks, MD, USA) with and without supplementation with
mycobactin J (Allied Monitor, Fayette, MO, USA). CFU obtained
from 3 HEYM tubes were averaged and adjusted to represent final
CFU per gram of feces.
Specimens of tonsil, submandibular lymph nodes, mesenteric
lymph nodes, ileocecal lymph nodes, liver, spleen, duodenum,
jejunum, ileum and spiral colon were obtained at necropsy for
mycobacterial culture. Each tissue specimen was trimmed and
weighed to achieve a 2 g specimen, decontaminated, blended in
a stomacher and cultured as previously described (Hines et al.,
1998, 2007a). A 0.5 ml aliquot of this tissue suspension was
saved for tissue PCR analysis. HEYM tubes with and without
mycobactin J were incubated at 37◦ C and observed weekly for
a minimum of 16 weeks at which time visible colonies were
counted. All positive mycobacterial cultures were confirmed by
PCR targeting IS900 (Rajeev et al., 2005). CFU obtained from 3
HEYM tubes were averaged and adjusted to represent final CFU
per gram of tissue (CFU/g).

Serum collected from the goats pre- and post-vaccination and
inoculation, and monthly thereafter, was evaluated by AGID and
ELISA. Reagents and methods of the Johne’s AGID protocol at the
New York Animal Health Diagnostic Laboratory (NYAHDL) were
used for AGID testing (personal communication, Susan Stehman,
Cornell University, NY, USA). ELISA testing was done using
a commercially-available USDA approved ELISA kit for goats
(Parachek®, Biocor Animal Health, Omaha, NE, USA), according
to manufacturer’s recommendations.

PCR VERIFICATION OF MAP STRAINS RECOVERED FROM FECES TO
EVALUATE PERSISTENCE

INTRADERMAL SKIN TESTING

Standard M. bovis PPD (serial # 10033X), M. avium PPD (serial
# 30-EXP-0303) and Johnin PPD (Johnin OT serial # 133–8705)
were obtained from NVSL (Ames, IA, USA). One-tenth ml
of each PPD was injected intradermally using standard tuberculin syringes on previously clipped skin of the cervical region.
Injection sites were marked with a black marker pen for easier
determination of injection site location. The kids were intradermal tested prior to vaccination, just prior to challenge, and
again prior to necropsy. The cervical side was alternated between
each series of PPD skin tests. The response to the PPD injections
(skin thickness/induration) was measured using calipers at 72 h
post-injection.

FECAL AND TISSUE PCR

The DNA from monthly fecal specimens and tissues obtained
from necropsy (tonsil, submandibular lymph nodes, mesenteric lymph nodes, ileocecal lymph nodes, liver, spleen, duodenum, jejunum, ileum, and spiral colon) were extracted using
a Qiagen tissue DNA extraction protocol per manufacturer’s
instructions. PCR to detect MAP in feces and necropsy tissues targeting IS MAP02 (Stabel and Bannantine, 2005) was performed
using the 4405545 AgPath-ID™ MAP (Johne’s) Reagent Kit (Life
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STATISTICAL ANALYSIS

Univariate analysis at each time point was conducted, to see if
there were any differences between groups in the outcome measure. Because the data were sparse in some months, Fisher’s
Exact Test in PROC FREQ of SAS (SAS Institute, 2009) was used
for categorical analyses (e.g., whether a goat tested Positive or
Negative in a particular month). PROC UNIVARIATE of SAS
(SAS Institute, 2009) was used to determine the mean and median
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AMT 39
AMT 859

jdip019_R1

jdip019_R2

jdip019_R2

CTC TTG CTC TTC CGC TTC TTC TCC

TAA TAC GAC TCA CTA TAG GG

TGC AGC AAC GCC AGG TCC ACA CT

GTA ATA CGA CTC ACT ATA GGG CNN NNC ATG

(sequencing primer)

TTGCTCTTCCGCTTCTTCT

CCCAAGCTTGGGTATTCGCTGCACAGCATGTCAGGT

GCTCTAGAGCTGGCATCAGGGCACTCAAGAAA

CCACCGTCACCGCAGGTAGA

GCTGCAGCAACCAGCCGA

CCCAAGCTTGGGTATTCGCTGCACAGCATGTCAGGT

genes are encoded in opposite directions, away from the POI.

lost upon further replication.
*Shin et al. (2006).

2 Transposon

1 These

AMT 38
AMT 858

jdip019_R1

329/fabG2_2*

MAP1566
Reverse

jdip009-R
AMT152

MAP1566
Forward

2E11-IP-R

2E11-IP-F

jdip009-F

jdip006-R

jdip006-F

318/40A940A9

319/30H9

316/2E11

MAP1566
Reverse

jdip005-R

19

36

32

20

18

36

32

Length

ORF

792
513

MAP0282c

1074

1074

1836

MAP0283c2

MAP1566

MAP36951

FadE51

MAP1566

ORF

1074

MAP1566
Forward

jdip005-F

GCTCTAGAGCTGGCATCAGGGCACTCAAGAAA

Sequence (5 -3 )

315/STM68

Name
size

JDIP ID#

Strains

Mutant

Table 3 | PCR primers used to detect survival of MAP mutant vaccine strains.

N/A

272

30 bp
upstream

137 bp
upstream

1032

POI

WT

N/A

1179

1845

1179

amplicon

Mutant

N/A

4575

5241

3700
estimated

amplicon
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values of numerical variables (e.g., culture CFU) in a particular
month.
However, because the time points are not independent from
each other, a mixed model, accounting for the correlation
between months, was used [PROC MIXED in SAS (SAS Institute,
2009)] for numerical outcomes. Two sets of models were fitted,
the first including all months, and the second excluding months
for which the values were all 0. Month was the repeated factor,
Goat ID was the subject factor, and an autoregressive covariance
structure (this assumes that measurements taken closer together
in time are more highly correlated than those taken further apart
in time) was used. For weight and BCS (only one outcome),
general linear models (PROC GLM of SAS, SAS Institute, 2009)
were used. PROC GLM was also used to look at, e.g., CFU
within each month. Pairwise differences between groups were
studied.
PROC LIFETEST of SAS (SAS Institute, 2009) was used to
generate Kaplan-Meier plots, with group as the stratification variable. Time (months) to the first Positive result was of interest.
If the goat had all negative results (i.e., still tested negative at
Month 15), it was censored (i.e., did not experience the event
of interest). However, some groups (1 and 2) did not have any
events, so “the likelihood ratio test for strata homogeneity is
questionable.” Therefore, this was run again, omitting Groups
1 and 2. Tests of Equality over Strata [Log-Rank, Wilcoxon,
−2 Log (Likelihood Ratio)] indicated whether there were differences among the groups, with respect to time to first positive
result.
Because many of the raw data values (e.g., CFU) have great
variation, the natural logarithm of these values was taken, to
normalize the data, and the above analyses were re-run. To overcome the large variation in absolute values, which can cause
problems in parametric analysis, a non-parametric approach
was used, based on ranks of the groups. Within each outcome
measure and time point, the groups were ranked, from 1 =
best-performing (e.g., low CFU, or low proportion of positive
responses) to 8 = worst-performing (e.g., high CFU, or high proportion of positive responses). Overall ranks were then obtained
for each outcome measure, over time. The analysis was done in
SAS’s PROC NPAR1WAY (SAS Institute, 2009). In all analyses,
statistical significance was assumed at P < 0.05.

RESULTS
MORBIDITY AND MORTALITY NOT ATTRIBUTABLE TO JOHNE’S
DISEASE

All 80 kids completed the study. Only occasional mild injuries
occurred during the 13 months in our BSL-2 facility. Infestation
with anthelmintic resistant Haemonchus spp. nematodes initially
necessitated a monthly deworming schedule using a combination of Moxidectin and Albendazole orally, but after 6 months
intestinal nematodes were eliminated. Sporadic mild clinical cases
of intestinal coccidiosis required periodic 10 day treatments of
the entire flock (all groups, challenged or non-challenged) with
Amprolium (Corid®, Merial Limited, Iselin, NJ, USA) administered in drinking water tanks. A few kids within all groups
had low numbers of Monezia spp. tapeworms in the small
intestine.
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CLINICAL SIGNS ATTRIBUTABLE TO JOHNE’S DISEASE

No appreciable differences were detected between any of the
treatment groups throughout the study in average daily weight
gain evaluated just before necropsy (data not shown). Body condition score of goats in group 1 (negative control) was higher than
that in groups 3 (316 vaccinated; P < 0.05) and 4 (315 vaccinated;
P < 0.05). Body condition score was higher in goats in group 7
(329 vaccinated) than in goats in groups 3 (316 vaccinated), 4
(315 vaccinated), 5 (319 vaccinated), 6 (318 vaccinated), and 8
(positive control) (P-values all less than 0.05) (data not shown).
Distinct clinical signs attributable to JD were not observed in
any challenged kids during the first 11 months post-challenge.
However, in the last few weeks of the study, one kid in group
4 given the 315 vaccine and 2 kids in group 6 given the 318
vaccine began to manifest mild clinical signs including weight
loss, decreased body condition scores, rough hair coat and minimal diarrhea (pasty non-pelleted feces) and had body condition
scores ≤2 consistent with JD. None of the challenged animals in
the positive control group (8) or Silirum® vaccinated group (2)
manifested obvious clinical signs of JD.
EFFECTS OF VACCINE ON ANTEMORTEM VACCINATION SITE
REACTION

Tissue reaction at the Silirum® vaccination site in group 2 kids
was measured pre-vaccination, at 2 months, at 6 months and
again at 13 months post-vaccination (data not shown). Reactions
consisted of localized swelling of the subcutis and overlying skin
with formation of a variable-sized firm subcutaneous nodule
approximately 1–2 weeks post-vaccination that decreased in size
over time, but persisted in most cases to the end of the study.
Hair loss or ulceration at the injection sites were not detected.
The one dimensional thickness of any subcutaneous nodule (vaccine granuloma) and overlying skin at the vaccination sites in
the brisket region was measured using calipers. If a reaction was
not detectable at a vaccination site by palpation, the average skin
thickness of the injection site was used. Only a single Silirum®
vaccinated kid (#30) developed abscessation with drainage at the
injection site. The maximum size of the tissue reaction ranged
between 25–30 mm and generally occurred at 1–2 weeks postvaccination and regressed slowly over time. Vaccine tissue reactions of 7–10 mm were still present in 40% of Silirum® vaccinated
kids at necropsy. Histopathology of these remaining vaccination
reactions revealed a nodular granuloma comprised of granulomatous inflammation admixed with lymphocytes and plasma cells
with occasional foci of necrosis surrounded by granulation tissue and fibrosis. None of the experimental vaccines were given by
injection.
EFFECTS OF VACCINE ON GROSS LESIONS

Kids in challenged groups 3–8 had moderate to severe gross
lesions consisting primarily of moderate to marked mesenteric
and ileocecal lymph node enlargement with numerous variablesized (1–10 mm) cortical tan foci of granulomatous inflammation. Occasional kids in these groups had mild to moderate
thickening of the ileal and jejunal mucosa, but obvious corrugation was not detected. Some kids in groups 3–8 had prominent
gross enlargement of lymphatics with associated lymphangitis.
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Challenged kids in group 2 (Silirum® vaccinated) showed minimal to mild gross lesions consisting primarily of mild mesenteric
and ileocecal lymph node enlargement with occasional small cortical 1–3 mm tan foci of granulomatous inflammation. Obvious
thickening of the small intestinal mucosa in these groups was
generally not evident.
EFFECTS OF VACCINE ON TISSUE MICROSCOPIC LESIONS

Tonsil and submandibular lymph nodes

Microscopic lesions consisting of variable but usually low numbers of microgranulomas (granulomas with less than approximately 30 macrophages) were detected in submandibular lymph
nodes, as well as tonsil in occasional kids of the challenged groups.
Only rarely were microgranulomas detected in submandibular lymph nodes or tonsil in kids given the Silirum® vaccine
(group 2). No granulomatous lesions were detected in these tissues from kids within the non-challenged negative control group
(group 1).
Mesenteric and ileocecal lymph nodes

The mesenteric and ileocecal lymph nodes of non-challenged
control kids (group 1) often had mild to moderate lymphoid
hyperplasia with mild medullary histiocytosis and scattered
medullary clusters of eosinophils. Lesions in mesenteric and
ileocecal lymph nodes of challenged kids varied in degree of
severity but were generally similar. These lesions consisted of
variable numbers of microgranulomas, scattered patchy foci of
granulomatous inflammation containing occasional multinucleate Langhan’s giant cells and variable numbers of acid-fast bacilli
primarily within the cortex of the nodes. In more severe cases,
the microgranulomas and patchy foci of granulomatous inflammation tended to coalesce to form large granulomas or sheets
of granulomatous inflammation containing variable numbers of
Langhan’s multinucleate giant cells and more numerous acid-fast
bacilli. The number of acid-fast bacilli was generally lower in
lymph nodes from group 2 (Silirum® vaccinated) than in group
4 (315 vaccinated) (P < 0.05); and lower in groups 2 (Silirum®;
P = 0.05), 3 (316 vaccinated; P < 0.05), and 7 (329 vaccinated;
P < 0.05) than in group 8 (positive control).
Intestines

All kids in all groups (challenged and non-challenged) had
varying degrees (mild to moderate) of lymphoplasmacytic,
eosinophilic and globule leukocyte infiltrate within all sections of
small intestine consistent with parasitic enteritis (Figure 1A). No
non-challenged kids in any group had granulomatous lesions or
acid-fast bacilli compatible with JD. The small intestinal lesions
attributable to JD consisted of microgranulomas, granulomas
and patchy foci of granulomatous inflammation with epithelioid macrophages, variable numbers of multinucleate Langhan’s
giant cells and acid-fast bacilli within the mucosa, submucosa
and Peyer’s patches. The intestinal lesions were most severe in
the terminal jejunum, less severe in the proximal jejunum and
ileum and only evident in the duodenum within occasional more
severely affected kids in groups 4 (315 vaccine), 5 (319 vaccine), and 8 (positive control). Lesion scores (Figure 2) were
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lower in group 2 (Silirum® vaccine) than in group 5 (319 vaccine; P < 0.05). Lesion scores were lower in groups 2 (Silirum®;
P < 0.05), 6 (318 vaccine; P ≤ 0.05), and 7 (329 vaccine; P ≤
0.05) than in group 8 (positive control). Variable degrees of lymphatic dilation and associated granulomatous lymphangitis were
present in these groups. Most kids in group 2 given the Silirum®
vaccine had lower numbers of microgranulomas, foci of granulomatous inflammation, Langhan’s giant cells and acid-fast bacilli
(Figure 1B). In groups 4 (315 vaccine), 5 (319 vaccine), and
8 (positive control) these lesions were of greater severity and
granulomatous foci often coalesced to form large sheets of epithelioid macrophages containing numerous acid-fast bacilli and less
Langhan’s giant cells within the mucosa, submucosa and Peyer’s
patches of the small intestine (Figure 1C) and occasional small
foci of granulomatous inflammation (microgranulomas) were
present in the large intestine. The 329 vaccine showed the least
lesion score among all the attenuated vaccines, although it was
not statistically significantly different from the other attenuated
vaccines.
Other organs

The liver was the only other organ where lesions and/or acidfast bacilli compatible with JD were detected. The liver lesions in
challenged kids consisted of variable numbers of microgranulomas, rare Langhan’s giant cells and rare acid-fast bacilli that were
present in most kids from all challenged groups. Liver microgranulomas were more common in groups 3–8 and only rarely present
in group 2 (Silirum® vaccine) kids.
EFFECTS OF VACCINE ON LESION SCORE

All kids in all challenged groups had at least subtle lesions
compatible with JD suggesting none of the vaccines completely
abrogated infection. Only the control vaccine appeared to show
a reduction in mean lesion score at 13 months post-challenge
(Figure 2), compared with the positive control (P < 0.05). The
319 vaccine showed a slightly higher (+11.9%; P = 0.17) lesion
score than the sham-vaccinated challenged positive control group
(group 8), and the 318 and 329 vaccine groups (groups 6 and 7)
showed a slightly lower lesion score [−15.7% (P < 0.05) and
−18.4% (P < 0.05) respectively] than group 8. Mean lesion
scores from groups 3–8 did not appear statistically different from
each other.
EFFECTS OF VACCINE ON FECAL SHEDDING OF MAP

The effect of vaccination on fecal shedding was determined by
both fecal culture and fecal PCR. There was an initial spike of
fecal shedding (Figure 3) at 7 months post-challenge that subsided by 8 months post-challenge, but returned by 9 months
and persisted to the end of the study in most groups with the
exception of group 2 (Silirum® vaccine). The Silirum® vaccine
(group 2—Figure 3) showed a reduction in fecal CFU/g at all
time points post-challenge as compared to the positive control
group (8) although this reduction was not statistically significant
(P = 0.06). The 315, 316, 318, and 329 vaccines (groups 3–6) had
similar levels of fecal shedding as compared to the positive control group and the 329 vaccine (group 7) had slightly less shedding
(but comparable; P = 0.10) than the positive control group.
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FIGURE 2 | Necropsy lesion scores for the challenged control and
experimental groups at 13 months post-challenge. All negative controls
(group 1, non-challenged kids) had lesion scores of 0. (Error bars represent
standard error of the mean).

FIGURE 3 | Monthly fecal culture results on Herrold’s Egg Yolk medium
with and without mycobactin J throughout the study. No positive
samples were detected in the non-challenged control group. (Error bars
represent standard error of the mean, −1 is baseline bleeding, 0 is
challenge date and 1–13 represents months post-challenge).

FIGURE 1 | (A–C) Note how the severity of microscopic lesions
increases along with the lesion score. Arrowheads indicate foci of
granulomatous inflammatory infiltrate. (A) Representative Hematoxylin
and Eosin stained section of non-challenged Sham vaccinated control
ileum sample (100X). Lesion score = 0. (B) Hematoxylin and Eosin
stained section of Silirum® vaccinated and challenged ileum sample
(100X). Inset shows Kinouyan’s acid-fast stain with a single acid-fast
bacillus in center from area labeled with a small star (600X). Lesion
score = 3.54. (C) Hematoxylin and Eosin stained section of higher
lesion score in a 319 vaccine (group 5) ileum sample (100X). Inset
shows Kinouyan’s acid-fast stain with multiple acid-fast bacilli from area
labeled by a small star (600X). Lesion score = 10.42.
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AgPath-ID™ MAP PCR was performed on the monthly fecal
specimens obtained from all kids in the study. Both fecal PCR
CT values and Positive/Negative results were obtained. Figure 4
shows the results of fecal PCR over time represented as percent
positive samples. No PCR positive samples were detected in the
negative control group (group 1) throughout the study. Sporadic
PCR positive samples were detected from 0 to 5 months postchallenge in several treatment groups. Beginning at 5–6 months
post-challenge all challenged groups progressively increased in
PCR positivity. At 9 months post-challenge the Silirum® vaccinated group percent positivity leveled off at 40–50% and
remained near this level till the end of the study, while all other
challenged groups continued to increase to near 100% positivity
by the end of the study.
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P < 0.05) showed reductions in percent positivity as compared
to the positive control group (group 8).
AGID

The results of AGID testing are shown in Figure 5. No nonchallenged kids (group 1) became AGID positive during the study.
All kids in challenged groups remained negative on the AGID test
until 8 months post-challenge. The percentage of AGID positive
animals in remaining challenged groups increased from 8 months
to 13 months. However, no animals in group 2 (Silirum® vaccine) had become positive by the end of the study, and only 1 kid
in group 7 (329 vaccine) became positive on the AGID test at 13
months post-challenge.
FIGURE 4 | Monthly fecal AgPath-ID™ PCR results throughout the
study. No positive samples were detected in the non-challenged control
group. (−1 is baseline bleeding, 0 is challenge date and 1–13 represents
months post-challenge).

To determine the persistence of the vaccine strains on fecal
shedding, primers were designed to amplify target regions specific to each knockout mutant vaccine yet able to distinguish
vaccine from challenge strains based on product size. PCR amplifications were performed on selected colonies obtained from fecal
culture of multiple goats from each group given one of the live
mutant vaccines. Only the challenge strain was identified from
the amplified products. The vaccine strains were not among any
of the colonies suggesting that they were not persistent in the
goats. For in vitro cultures, amplification was not successful using
primers from vaccines 318 and 329 due to the instability of the
corresponding mutations (Raul G. Barletta and Adel M. Talaat,
unpublished results). Amplicons specific for insertions in other
vaccine candidates were identified correctly.
EFFECTS ON TISSUE COLONIZATION OF MAP

In intestinal tissues, kids vaccinated with Silirum® (group 2) had
dramatically lower mean numbers of MAP CFU/g than the positive control group (8) (P-value range 0.0013–0.1044). As shown
in Table 4, mean MAP CFU/g cultured from each tissue individually were reduced by 10+ fold in most tissues from Silirum®
vaccinated kids. Kids vaccinated with the 315 and 319 vaccines
(groups 4 and 5) had in general higher (although not statistically significant) CFU/g in most tissues than those of the positive
control group (group 8). In general, either no or very low MAP
CFU/g were cultured from non-intestinal tissues (liver, spleen,
tonsil, and submandibular lymph nodes) in all challenged groups.
The highest numbers of CFU/g were cultured from intestinal
tissues including mesenteric and ileocecal lymph nodes, ileum,
jejunum and duodenum, but much lower numbers were cultured
from spiral colon.
AgPath-ID™ MAP PCR was performed on the tissue specimens obtained from all goats at necropsy. Both tissue PCR CT
values and Positive/Negative results were obtained. Table 5 shows
the tissue PCR results represented as percent positive samples. No
PCR positive samples were detected in the negative control group
(group 1) throughout the study. Only the Silirum® vaccinated
group (group 2; P < 0.05) and 329 vaccinated group (group 7;
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ELISA

Optical density measurements of the Parachek® ELISA over time
are shown in Figure 6. Sensitivity values of the ELISA test, from
1 to 7 months, 1 to 9 months, and 1 to 15 months, for each of
the six vaccines, are shown in Table 6; the cutoff value was set
at ELISA_OD = 0.25. If the ELISA test was positive at any time
point in the interval, the animal was considered to be positive.
Sensitivity improved as the study progressed. Vaccination with
the Silirum® vaccine (group 2) resulted in an almost immediate
rise in ELISA OD values that leveled off at 3–4 months postchallenge, tended to fluctuate slightly and trend slightly lower,
but persisted throughout the study. None of the sham-vaccinated
non-challenged kids (group 1) developed significant OD values.
ELISA OD values in the remaining groups (groups 3–8) began
to rise between 4 and 6 months and continued to rise through
the remainder of the study as the disease progressed. Sensitivity
and specificity are usually used to assess test performance. In
this study, the same test (ELISA) was used in different vaccine
groups to see how it performed with different vaccines (Table 6).
That is, the test per se is constant, but the vaccines (experimental
treatments) are variable.
PPD SKIN TESTS

Three comparative cervical PPD skin tests including M. avium
PPD, M. bovis PPD, and Johnin PPD were performed at the beginning of the study, after vaccination but prior to challenge and
before necropsy (13 months post-challenge). Results of PPD skin
testing over time are shown in Figures 7A–C. When a 2.0 mm
cutoff above normal skin thickness was used for positive skin
test reactions, spontaneous false-positive PPD skin test reactions
were common in all groups for M. avium. Vaccination resulted
in false-positive PPD skin test reactions for M. avium PPD in the
Silirum®, 315, 316, and 319 vaccinated groups, and Johnin PPD
in the Silirum® and 316 vaccinated groups. When a 2.0 mm cutoff above normal skin thickness was used for positive skin test
reactions, false-positive reactions for M. bovis were detected particularly in the Silirum® vaccinated group and to a lesser extent
in the 316 and 329 groups, and remained consistently negative in
the three time points evaluated for vaccines 315 and 318.
Overall, there was a significant difference in ranking of treatment groups in the skin tests (combined). Goats in the 318 and
315 groups had lower skin thickness (across all tests) than did
goats in the positive control group (P = 0.0011 and P = 0.0037,
respectively).
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Table 4 | HEYM tissue culture (CFU/gm) means and ranges, by vaccine group (rounded to nearest whole number).
Tissues

(−) control

Silirum®

316 vaccine

315 vaccine

319 vaccine

318 vaccine

329 vaccine

(+) control

Group

1

2

3

4

5

6

7

8

Liver
Spleen
Tonsil
Submandibular LN
Mesenteric LN-1
Mesenteric LN-2
Ileocecal LN
Ileum
Jejunum-1
Jejunum-2
Jejunum-3
Duodenum
Spiral colon

0

0

0

37

13

1

76

1

(0–0)

(0–0)

(0–2)

(0–197)

(0–101)

(0–3)

(0–749)

(0–8)

0

0

1

5

1

0

0

1

(0–0)

(0–0)

(0–6)

(0–43)

(0–5)

(0–2)

(0–0)

(0–13)

0

0

1

1

0

0

0

0

(0–0)

(0–0)

(0–3)

(0–6)

(0–2)

(0–0)

(0–2)

(0–0)

0

0

0

14

0

0

0

0

(0–0)

(0–0)

(0–0)

(0–102)

(0–2)

(0–2)

(0–0)

(0–0)

0

55

511

1095

964

651

480

772

(0–0)

(0–477)

(0–1440)

(2–1440)

(59–1440)

(0–1440)

(0–1440)

(2–1440)

0

86

616

797

926

620

653

828

(0–0)

(0–757)

(0–1440)

(0–1440)

(30–1440)

(0–1440)

(0–1440)

(11–1440)

0

63

412

770

980

727

536

589

(0–0)

(0–259)

(0–1440)

(0–1440)

(13–1440)

(0–1440)

(0–1440)

(16–1440)

0

5

240

585

564

397

175

362

(0–0)

(0–22)

(0–1440)

(0–1440)

(0–1440)

(0–1440)

(0–1440)

(0–1440)

0

33

448

893

958

569

323

870

(0–0)

(0–98)

(0–1440)

(2–1440)

(130–1440)

(0–1440)

(0–1440)

(19–1440)

0

87

614

1053

858

583

351

720

(0–0)

(0–786)

(0–1440)

(0–1440)

(5–1440)

(0–1440)

(0–1440)

(53–1440)

0

7

474

883

598

804

454

619

(0–0)

(0–19)

(0–1440)

(0–1440)

(18–1440)

(0–1440)

(0–1440)

(10–1440)

0

1

107

722

422

192

91

353

(0–0)

(0–5)

(0–885)

(0–1440)

(0–1440)

(0–1440)

(0–878)

(0–1440)

0

0

44

227

204

27

4

9

(0–0)

(0–0)

(0–235)

(0–1440)

(0–1440)

(0–168)

(0–22)

(0–78)

LN, Lymph node.

Table 5 | Tissue AgPath-ID MAP PCR percent positive.
Tissues

(−) control

Silirum®

316 vaccine

315 vaccine

319 vaccine

318 vaccine

329 vaccine

(+) control

Group

1

2

3

4

5

6

7

8

Liver

0

0

90

100

60

60

30

70

Spleen

0

0

70

90

40

50

40

60

Tonsil

0

0

70

70

80

50

40

90

Submandibular LN

0

10

90

60

60

50

30

60

Mesenteric LN-1

0

70

100

70

100

100

90

100

Mesenteric LN-2

0

70

100

70

100

90

90

90

Ileocecal LN

0

60

90

80

100

90

50

100

Ileum

0

50

90

100

90

90

80

100

Jejunum-1

0

60

100

100

90

80

80

100

Jejunum-2

0

70

100

100

100

100

90

100

Jejunum-3

0

70

100

90

100

100

90

100

Duodenum

0

0

100

100

80

50

50

70

Spiral Colon

0

0

80

100

60

60

50

90

LN, Lymph node.

DISCUSSION
Development of an effective control strategy against Johne’s disease in dairy herds remains an elusive goal despite the presence of
commercial vaccines for cattle (Mycopar®) and small ruminants
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(Silirum®). With the development of molecular and genomic
tools to study MAP, the causative agent of JD, we sought to
take a rational approach for developing live attenuated vaccine
by focusing on MAP mutants that were shown to be attenuated
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Table 6 | Sensitivity (%) of the Parachek ELISA, by vaccine. The
cutoff value was set at ELISA_OD = 0.25.
Vaccine (group)
Silirum® (2)

FIGURE 5 | New York Animal Health Diagnostic Laboratory (NYAHDL)
AGID test results over time. The NYAHDL AGID is an agar gel
immunodiffusion test for measuring serum antibody to Mycobacterium
avium subsp. paratuberculosis. Note that no animals in the Silirum®
vaccine group and only 1 animal in the 329 vaccine group (group 7) became
AGID positive. (−1 is baseline bleeding, 0 is challenge date and 1–13
represents months post-challenge).

FIGURE 6 | Parachek® ELISA optical density (OD) readings over time.
Note the almost immediate increase in ELISA OD for the Silirum®
vaccinated group, the progressive increase in ELISA OD in most vaccine
groups beginning around 5 months post-challenge and the leveling off of
the Silirum® vaccinated group OD values at 9–13 months post-challenge.
(Error bars represent standard error of the mean, −1 is baseline bleeding, 0
is challenge date and 1–13 represents months post-challenge).

during infection (Shin et al., 2006). Drs. Barletta and Talaat have
now generated stable deletion mutants that could be tested in
a second trial with the methods reported in this manuscript.
However, at the time this phase of the efficacy project was started
genetically stable versions of these mutants were not yet available. The primary goals of this study were to (1) to evaluate
the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control, and (2) to validate the
AMSC Johne’s disease goat challenge model (see Hines et al.,
2007b). However, another goal of our study was to develop an
easy-to-administer oral vaccine against JD in comparison to the
commercially available vaccines administered via subcutaneous
injection.
All challenged baby goats (kids) in the study had lesions
compatible with JD suggesting none of the vaccines prevented
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Months 1–7

Months 1–9

Months 1–15

100

100

100

316 (3)

0

20

60

315 (4)

0

0

60

319 (5)

10

10

100

318 (6)

10

30

50

329 (7)

10

30

50

infection and that the goat model used in this study is highly
efficient (100%) in producing active JD in challenged goats. As
expected, none of the unchallenged kids had gross or microscopic
lesions compatible with JD. The gross and microscopic lesions
observed in this study were generally similar to those described
previously (Clarke, 1997; Storset et al., 2001; Munjal et al., 2005;
Hines et al., 2007a).
A key disadvantage of currently licensed vaccines is the development of skin lesions at the site of inoculation. In this study,
ante-mortem vaccine site reaction was not an issue with the
experimental vaccines as they were given by the oral route.
However, the control vaccine used in our study produced significant tissue reaction at the injection site that persisted to the
end of the study in approximately 40% of the kids in group 2.
The control vaccine group (group 2, Silirum®) showed a marked
reduction in fecal CFU/g at all time points post-challenge and
a lesser reduction in fecal CFU/g was found with one of the
experimental vaccines (vaccine 329). However, wide variation in
fecal and tissue MAP CFU/g occurred both among and within
groups, which reduced statistical power and probably indicates
the need for evaluation of larger numbers of animals in future
studies. A similar pattern was observed for the lesions scores
and tissue colonization data obtained following histological and
bacteriological analyses. It is noteworthy to mention here that
the mean MAP CFU/g cultured from individual tissues were
reduced by 10+ fold in most tissues from control vaccinated
kids (group 2, Silirum®). These data also suggest that spread of
MAP infection is limited beyond the intestine in the Silirum®
vaccinated goats. Our findings are consistent with prior studies (Saxegaard and Fodstad, 1985; Fridriksdottir et al., 2000;
Reddacliff et al., 2006; Hines et al., 2007a) that show that “whole
cell” bacterins can reduce fecal shedding of MAP. However, this
relationship was not evident in other studies (Wentink et al.,
1994; Koets et al., 2000, 2006). It is possible that subcutaneous
inoculation of the experimental mutant vaccines could provide a
similar shedding pattern to that observed in the control vaccine
group.
Real time PCR using the AgPath-ID™ PCR test (Figure 4) was
able to detect the presence of MAP within feces significantly earlier than HEYM fecal culture and likely detected the 315 vaccine
strain at 0 months post-challenge (prior to administration of the
challenge). MAP was detected by PCR in some animals from the
Silirum®, 315 and 318 vaccinated groups at 2–3 months postchallenge that is likely due to the challenge MAP strain, but in
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FIGURE 7 | (A–C) PPD skin test results over time. Note the strong skin
responses to M. avium (A) and Johnin (C) PPD in multiple groups, and the
generally lower responses to M. bovis (B) PPD with the exception of the
Silirum® and 316 vaccines. (Error bars represent standard error of the
mean, −1 is baseline bleeding, 0 is challenge date and 1–13 represents
months post-challenge).

the 315 and 318 vaccinated groups the vaccine strains MAP could
have still been present and contributed.
The dependence of JD control programs on diagnostic
tests based on the immune responses generated after exposure/infection with MAP complicates the widespread use of JD
vaccines in the field. All kids in challenged groups remained negative on the AGID test until 8 months post-challenge, none of
the control vaccinated kids ever became positive on AGID and
only one animal in the 329 vaccine group became positive on
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AGID. These findings demonstrate the limited usefulness of the
AGID test as it tends to only detect the more advanced cases of
JD in goats. Subcutaneous vaccination with the Silirum® vaccine (group 2, positive control vaccine) resulted in an almost
immediate rise in ELISA OD values after vaccination that leveled off at 3–4 months post-challenge, tended to fluctuate slightly
and trend slightly lower over time, but persisted throughout
the study. None of the sham-vaccinated non-challenged kids
(group 1) developed significant OD values. ELISA OD values in
the remaining groups (groups 3–8, experimental vaccines and
positive control group) began to rise between 5 and 8 months
post-challenge and continued to rise through the remainder
of the study as the disease progressed. Since all experimental
mutant vaccines were administered by the oral route, this may
explain why ELISA OD values in these vaccines were initially
subdued and humoral immunity was delayed until 5–8 months
post-challenge.
Another complication of using whole bacterin or live attenuated vaccine is the cross reactivity to skin testing for M. bovis
infection or for even natural infection with field isolates of MAP.
Our analysis indicated that spontaneous false-positive PPD skin
test reactions were common in all groups for M. avium even prior
to vaccination. This is not uncommon due to the high exposure to environmental mycobacteria within the southeastern US
which complicates the interpretation of skin test and γ-interferon
results. Vaccination resulted in false-positive PPD skin test reactions for M. avium PPD in control, Silirum®, 315, 316 and 319
vaccinated groups, and Johnin PPD in the Silirum® and 316 vaccinated groups. When a 2.0 mm cutoff above normal skin thickness
was used for positive skin test reactions, false-positive reactions
for M. bovis were detected particularly in the Silirum® vaccinated
group and to a lesser extent in the 316 and 329 groups. These
findings indicate that several of the vaccines and particularly the
Silirum® vaccine significantly impact the results of PPD skin
testing and produce false positive results with the tuberculosis
(M. bovis) skin test that may impact tuberculosis control testing
programs.
Other reports evaluating the performance of attenuated
mutant MAP strains that include evaluation of live attenuated
vaccines in a ruminant model are sparse within the literature.
A recent report evaluated a MAP leuD mutant as a vaccine candidate in a goat challenge model (Faisal et al., 2013). However,
the study by Faisal and coauthors did not utilize the suggested
standardized challenge parameters proposed for goat challenge
models by the AMSC. Their study did not include a negative
non-challenged control group to prove that none of the animals
were infected before or during the study, Mycopar® was used
instead of Silirum® as a positive control vaccine, a non-K10-like
MAP strain was used as the challenge MAP strain, and persistence of the attenuated vaccine strain was not evaluated. In our
hands, not all of our vaccine constructs were stable during culturing, most likely because of their nature as transposon mutants.
In future experiments, using a stable mutant constructed by
allelic exchange, for example, could provide a better alternative.
Therefore, direct comparison of results between these two studies is not possible due to the number of extraneous variables
involved.
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CONCLUSIONS
We found that (1) The AMSC proposed standard goat MAP challenge model is highly efficient in producing infection in goats and
is a valid model for JD challenge and/or vaccine efficacy studies; (2) none of the control or experimental oral vaccines in this
study prevented MAP infection, although administration of the
329 vaccine lowered the incidence of infection and reduced lesion
scores; (3) only the control vaccine (Silirum®) showed a clear
reduction in lesion score, MAP fecal shedding and tissue colonization, but it induced tissue damage in the site of inoculation that
persisted in 40% of the animals; (4) based on evaluation of lesion
scores, fecal shedding and tissue colonization the relative performance ranking of the vaccines evaluated in this study Silirum®
was the best performer, then the 329 vaccine, 318 vaccine, 316
vaccine, 315 vaccine and the 319 vaccine was the worst performer;
and (5) oral delivery may not be a viable alternative to deliver live
attenuated vaccines against JD. Our results suggest that although
vaccination with Silirum® does not prevent infection or eliminate
MAP fecal shedding, it reduces presence of JD gross and microscopic lesions, slows progression of disease, reduces fecal shedding
and reduces tissue colonization.
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